Regeneron Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?
/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
With a market cap of $63.5 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a fully integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection, Dupixent Injection, Libtayo Injection, Praluent Injection, Kevzara Injection, and others.
Shares of REGN have significantly underperformed the broader market over the past 52 weeks. REGN has dropped 40% over this time frame, while the broader S&P 500 Index ($SPX) has gained 10.2%. Moreover, shares of REGN are down 17.4% on a YTD basis, compared to SPX’s 1.3% drop.
Looking closer, Regeneron has also lagged behind the iShares U.S. Healthcare ETF’s (IYH) 10.4% decline over the past year and 6.5% fall on a YTD basis.
Regeneron stock tumbled 6.9% following the release of its weaker-than-expected Q1 2025 results on Apr. 29. The company reported revenue of $3 billion, down 3.7% year-over-year, missing Wall Street expectations. The decline was primarily due to a double-digit drop in net product sales, including a 38.8% decline in legacy EYLEA, which outweighed the 53.5% growth in EYLEA HD. However, collaboration revenue rose 20.9%, driven by its partnership with Sanofi. Adjusted EPS came in at $8.22, marking a 13.9% decrease from the prior-year quarter and falling short of the analysts’ estimate of $8.43.
For the current fiscal year, ending in December 2025, analysts expect REGN’s adjusted EPS to drop 24.1% year-over-year to $29.32. The company's earnings surprise history is mixed. It beat the consensus estimates in three of the past four quarters while missing on another occasion.
Among the 25 analysts covering the stock, the consensus rating is a “Strong Buy.” That’s based on 20 “Strong Buy” ratings, one “Moderate Buy,” three “Holds,” and one “Moderate Sell.”
This configuration is slightly more bullish than three months ago, with 19 “Strong Buy” ratings on the stock.
On May 14, Citi analyst Geoff Meacham raised REGN’s price target to $700 and upgraded it to a “Buy” rating.
As of writing, Regeneron is trading below the mean price target of $803.58. The Street-high price target of $958 implies a potential upside of 62.8% from the current price levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.